These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33662011)

  • 1. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis.
    Lemieux S; Buies A; F Turgeon A; Hallet J; Daigle G; Côté F; Provencher S
    PLoS One; 2021; 16(3):e0247958. PubMed ID: 33662011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman O; Elsayed Z
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis.
    Zhang Y; Li Y; Ji H; Zhao X; Lu H
    Biosci Trends; 2015 Oct; 9(5):289-98. PubMed ID: 26559021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
    Lobo L; Yakoub D; Picado O; Ripat C; Pendola F; Sharma R; ElTawil R; Kwon D; Venkat S; Portelance L; Yechieli R
    Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1580-1588. PubMed ID: 27586657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma.
    Whitlock RS; Loo C; Patel K; Bista R; Goss JA; Heczey A; Khan O; Lopez-Terrada D; Masand P; Nguyen H; Mahvash A; Vasudevan SA; Kukreja K
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1181-e1185. PubMed ID: 33769387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Salem R; Lewandowski RJ
    Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
    Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
    Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer - a systematic review and network meta-analysis of survival data.
    Chow R; Simone CB; Jairam MP; Swaminath A; Boldt G; Lock M
    Acta Oncol; 2022 Apr; 61(4):484-494. PubMed ID: 34846988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France.
    Loffroy R; Ronot M; Greget M; Bouvier A; Mastier C; Sengel C; Tselikas L; Arnold D; Maleux G; Pelage JP; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; Urdániz M; Kaufmann N; Bilbao JI; Helmberger T; Vilgrain V;
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):36-49. PubMed ID: 32975600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
    Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
    J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.
    Jia Z; Jiang G; Tian F; Zhu C; Qin X
    Saudi J Gastroenterol; 2016; 22(5):353-359. PubMed ID: 27748320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
    Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization.
    Zhao K; Son S; Karimi A; Marinelli B; Erinjeri JP; Alexander ES; Sotirchos VS; Harding JJ; Soares KC; Ziv E; Covey A; Sofocleous CT; Yarmohammadi H
    Curr Oncol; 2024 May; 31(5):2650-2661. PubMed ID: 38785481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma.
    Kim Y; Lee HA; Lee JS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Seo YS; Kim SU
    Cancer Invest; 2021 Mar; 39(3):274-283. PubMed ID: 33356630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.